WTA
NBIX icon

Washington Trust Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Washington Trust Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-4,392
Closed -$428K – 918
2022
Q2 		$428K Sell
4,392
-2,655
-38% -$245K 0.04% 142
2022
Q1 		$661K Sell
7,047
-440
-6% -$37.3K 0.05% 135
2021
Q4 		$638K Buy
+7,487
New +$689K 0.04% 144

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Washington Trust Advisors's NBIX Position: Q3 2022 in Review

Washington Trust Advisors sold out of Neurocrine Biosciences (NBIX) in Q3 2022, closing a stake of 4,392 shares — an estimated $428K sold.

Washington Trust Advisors first reported a position in NBIX in Q4 2021 and held it in 3 quarters. The position peaked at $661K in Q1 2022. 466 funds tracked by Wall St. Rank hold NBIX as of Q3 2022.

  • Washington Trust Advisors reported no remaining Neurocrine Biosciences position as of Q3 2022 after selling out during the quarter.
  • Washington Trust Advisors sold 4,392 Neurocrine Biosciences shares in Q3 2022, an estimated $428K.
  • Washington Trust Advisors first reported a position in Neurocrine Biosciences in Q4 2021 and held it in 3 quarters.
  • Washington Trust Advisors's Neurocrine Biosciences position peaked at $661K in Q1 2022.
  • 466 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2022.

Based on Washington Trust Advisors's 13F filing for Q3 2022, filed 14 Oct 2022.